Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) saw a large growth in short interest in the month of April. As of April 15th, there was short interest totalling 48,980,000 shares, a growth of 5.6% from the March 31st total of 46,380,000 shares. Approximately 22.2% of the shares of the company are sold short. Based […]
Iovance Biotherapeutics (NASDAQ:IOVA – Get Free Report) is scheduled to announce its earnings results after the market closes on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.45) per share for the quarter. Iovance Biotherapeutics (NASDAQ:IOVA – Get Free Report) last posted its quarterly earnings data on Wednesday, February 28th. The biotechnology […]
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) has been given a consensus rating of “Buy” by the ten ratings firms that are presently covering the company, Marketbeat Ratings reports. Ten investment analysts have rated the stock with a buy rating. The average 12-month price target among brokers that have issued a report on the […]
Shares of Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) have been assigned a consensus recommendation of “Buy” from the ten brokerages that are covering the stock, MarketBeat reports. Ten research analysts have rated the stock with a buy rating. The average 12 month price objective among brokerages that have issued a report on the […]
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA – Get Free Report) has been assigned an average rating of “Buy” from the ten research firms that are covering the firm, MarketBeat reports. Ten analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokers that have updated their coverage on the stock in […]